A Randomized, Placebo-controlled, Phase II Pilot Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension

Trial Profile

A Randomized, Placebo-controlled, Phase II Pilot Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2014

At a glance

  • Drugs LJPC 501 (Primary)
  • Indications Hypotension
  • Focus Therapeutic Use
  • Sponsors La Jolla Pharmaceutical Company
  • Most Recent Events

    • 06 Aug 2014 New trial record
    • 08 Jul 2014 Results published in the La Jolla Pharmaceutical Company Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top